SEC Comment Letter 0000000000-24-010172 to KAZIA THERAPEUTICS LTD (KZIA) (CIK 0001075880) (KZIA)
KAZIA THERAPEUTICS LTD (KZIA) (CIK 0001075880)
Date: Sept. 9, 2024 · CIK: 0001075880 · Accession: 0000000000-24-010172
AI Filing Summary & Sentiment
File numbers found in text: 333-281937
Letter
September 9, 2024 John Friend Chief Executive Officer Kazia Therapeutics Limited Three International Towers Level 24, 300 Barangaroo Avenue Sydney, NSW, 2000, Australia Re:Kazia Therapeutics Limited Registration Statement on Form F-3 Filed September 5, 2024 File No. 333-281937 Dear John Friend: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Finn Murphy
Show Raw Text
September 9, 2024
John Friend
Chief Executive Officer
Kazia Therapeutics Limited
Three International Towers
Level 24, 300 Barangaroo Avenue
Sydney, NSW, 2000, Australia
Re:Kazia Therapeutics Limited
Registration Statement on Form F-3
Filed September 5, 2024
File No. 333-281937
Dear John Friend:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Finn Murphy